Ana Maria Giménez-Arnau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ana Maria Giménez-Arnau has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Marcus Maurer
Institute of Allergology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
2 shared publications - Maria-Magdalena Balp
Novartis Pharma AG, Basel, Switzerland
2 shared publications A. Bauer
Department of Dermatology, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany
1 shared publication- Alejandro Martin-Gorgojo
Madrid City Council, STI/Dermatology Department, 28006 Madrid, Spain
1 shared publication - Alla Nakonechna
Chest and Allergy Clinic Imperial College Healthcare NHS Foundation Trust London UK
1 shared publication - Andre C. Knulst
Department of Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands
1 shared publication
Latest Publications
- 16 April 2025
- Published by Elsevier in The Lancet
- Vol. 405 (10490) , 1676-1688
Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial
- 16 April 2025
- Published by Elsevier in The Lancet
- Vol. 405 (10490) , 1676-1688
Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial
- 26 October 2021
- Published by Springer Nature
- p. 227-246
Urticaria Therapy and Management. Looking Forward
- 26 October 2021
- Published by Springer Nature
- p. 227-246
Urticaria Therapy and Management. Looking Forward
- 29 June 2018
- Published by Springer Nature
- p. 1-12
Essentials and Updated Concepts
- 29 June 2018
- Published by Springer Nature
- p. 161-170
Management and Treatment of Contact Urticaria Syndrome
- 29 June 2018
- Published by Springer Nature
- p. 161-170
Management and Treatment of Contact Urticaria Syndrome
- 29 June 2018
- Published by Springer Nature
- p. 45-56
Clinical Diagnosis of Immediate Contact Skin Reactions
- 29 June 2018
- Published by Springer Nature
- p. 45-56
Clinical Diagnosis of Immediate Contact Skin Reactions
- 2 February 2017
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 17 (3) , 375-385
Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety
Introduction: Chronic spontaneous urticaria (CSU) is characterized by the recurrence of itchy hives and/or angioedema for greater than six weeks, with no known external trigger. Omalizumab, a humanized, recombinant, monoclonal anti-IgE antibody, is the only approved add-on therapy for H1-antihistamine refractory CSU patients. Areas covered: The objective of this article is to discuss the mechanism of action, pharmacokinetics and pharmacodynamics of omalizumab for the treatment of CSU. The review also summarizes efficacy and safety data from proof-of-concept, phase II (X-CUISITE, MYSTIQUE), and pivotal phase III omalizumab studies (ASTERIA I, ASTERIA II, and GLACIAL). Expert opinion: Omalizumab is a clinically effective and safe biological therapy for treating H1-antihistamine refractory CSU patients. It significantly reduces CSU symptoms (hives, itch and angioedema), and improves patient health-related quality of life. While omalizumab is already integral to the treatment of antihistamine refractory CSU, widespread use will depend on legal and economic factors, as well as improvements in the early and accurate diagnosis of CSU patients who would benefit from treatment.
- 2 February 2017
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 17 (3) , 375-385
Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety
Introduction: Chronic spontaneous urticaria (CSU) is characterized by the recurrence of itchy hives and/or angioedema for greater than six weeks, with no known external trigger. Omalizumab, a humanized, recombinant, monoclonal anti-IgE antibody, is the only approved add-on therapy for H1-antihistamine refractory CSU patients. Areas covered: The objective of this article is to discuss the mechanism of action, pharmacokinetics and pharmacodynamics of omalizumab for the treatment of CSU. The review also summarizes efficacy and safety data from proof-of-concept, phase II (X-CUISITE, MYSTIQUE), and pivotal phase III omalizumab studies (ASTERIA I, ASTERIA II, and GLACIAL). Expert opinion: Omalizumab is a clinically effective and safe biological therapy for treating H1-antihistamine refractory CSU patients. It significantly reduces CSU symptoms (hives, itch and angioedema), and improves patient health-related quality of life. While omalizumab is already integral to the treatment of antihistamine refractory CSU, widespread use will depend on legal and economic factors, as well as improvements in the early and accurate diagnosis of CSU patients who would benefit from treatment.
- 29 November 2016
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 31 (4) , 664-671
Contact allergy to preservatives: ESSCA* results with the baseline series, 2009–2012
Background: Allergic contact dermatitis caused by biocides is common and causes significant patient morbidity.Objective: To describe the current frequency and pattern of patch test reactivity to biocide allergens included in the baseline series of most European countries.Methods: Data collected by the European Surveillance System on Contact Allergies (ESSCA) network between 2009 and 2012 from 12 European countries were analysed.Results: Methylisothiazolinone 0.2% aq. produced the highest prevalence of sensitization during the study period, with an overall prevalence of 4.5%. The mixture methylchloroisothiazolinone /methylisothiazolinone tested at 0.02% aq. followed closely, with 4.1% of positive reactions. Other preservatives with lower rates of sensitization, but still over 1%, include methyldibromo glutaronitrile (MDBGN) 0.5% pet. and iodopropynyl butylcarbamate (IPBC) 0.2% pet. Formaldehyde releasers and parabens yielded less than 1% positive reactions during the study period. Some regional differences in the prevalence of contact allergy to biocides among European countries were observed.Conclusions: Contact allergy to biocides is common throughout Europe, and regional differences could be explained by differences in exposure or characteristics of the population tested. Timely regulatory action for isothiazolinones is required. Although MDBGN is banned from cosmetics products since 2005, sensitization prevalence has not appeared to plateau. IPBC is an emerging allergen with an increasing prevalence over the last few years, and its inclusion in the European baseline series may be appropriate.
- 29 November 2016
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 31 (4) , 664-671
Contact allergy to preservatives: ESSCA* results with the baseline series, 2009–2012
Background: Allergic contact dermatitis caused by biocides is common and causes significant patient morbidity.Objective: To describe the current frequency and pattern of patch test reactivity to biocide allergens included in the baseline series of most European countries.Methods: Data collected by the European Surveillance System on Contact Allergies (ESSCA) network between 2009 and 2012 from 12 European countries were analysed.Results: Methylisothiazolinone 0.2% aq. produced the highest prevalence of sensitization during the study period, with an overall prevalence of 4.5%. The mixture methylchloroisothiazolinone /methylisothiazolinone tested at 0.02% aq. followed closely, with 4.1% of positive reactions. Other preservatives with lower rates of sensitization, but still over 1%, include methyldibromo glutaronitrile (MDBGN) 0.5% pet. and iodopropynyl butylcarbamate (IPBC) 0.2% pet. Formaldehyde releasers and parabens yielded less than 1% positive reactions during the study period. Some regional differences in the prevalence of contact allergy to biocides among European countries were observed.Conclusions: Contact allergy to biocides is common throughout Europe, and regional differences could be explained by differences in exposure or characteristics of the population tested. Timely regulatory action for isothiazolinones is required. Although MDBGN is banned from cosmetics products since 2005, sensitization prevalence has not appeared to plateau. IPBC is an emerging allergen with an increasing prevalence over the last few years, and its inclusion in the European baseline series may be appropriate.
- Open Access
- 18 August 2016
- Published by Wiley in Clinical and Translational Allergy
- Vol. 6 (1) , 1-10
Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies
Patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) report difficulty with sleep. We examined the effect of omalizumab on sleep-related outcomes during 3–6 months omalizumab or placebo treatment and a 16-week follow-up period within three Phase III double-blind randomized placebo-controlled pivotal trials in CIU/CSU: ASTERIA I, ASTERIA II, and GLACIAL. Sleep quality was assessed in all three studies using sleep-related questions included in an electronic diary, the Chronic Urticaria Quality of Life Questionnaire, and the Medical Outcomes Study Sleep Scale. Score changes from baseline in the treatment arms were compared with that in the placebo arm and adjusted for baseline score and weight. We also examined correlations of sleep scores at baseline, week 12, and week 24 and the slopes of change between sleep and itch and hive. Patients treated with omalizumab reported a larger reduction in sleep problems than those in the placebo arm; omalizumab 300 mg demonstrated the greatest improvement on all sleep components among all treatment arms. The largest reduction in sleep problems was reported within the first 4 weeks of therapy. After treatment discontinuation, sleep quality worsened. Sleep scores demonstrated moderate-to-strong correlation between them, and the change in sleep scores was associated with changes in itch and hives. Improvement in sleep was reported after the first dose of omalizumab. Sleep continued to improve throughout the active treatment period. Patients receiving omalizumab 300 mg achieved greater improvement in sleep than those in other treatment arms. Trial registration ClinicalTrials.gov, NCT01287117 (ASTERIA I), NCT01292473 (ASTERIA II), and NCT01264939 (GLACIAL)
- 18 August 2016
- Published by Wiley in Clinical and Translational Allergy
- Vol. 6 (1) , 1-10
Open AccessImprovement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies
Patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) report difficulty with sleep. We examined the effect of omalizumab on sleep-related outcomes during 3–6 months omalizumab or placebo treatment and a 16-week follow-up period within three Phase III double-blind randomized placebo-controlled pivotal trials in CIU/CSU: ASTERIA I, ASTERIA II, and GLACIAL. Sleep quality was assessed in all three studies using sleep-related questions included in an electronic diary, the Chronic Urticaria Quality of Life Questionnaire, and the Medical Outcomes Study Sleep Scale. Score changes from baseline in the treatment arms were compared with that in the placebo arm and adjusted for baseline score and weight. We also examined correlations of sleep scores at baseline, week 12, and week 24 and the slopes of change between sleep and itch and hive. Patients treated with omalizumab reported a larger reduction in sleep problems than those in the placebo arm; omalizumab 300 mg demonstrated the greatest improvement on all sleep components among all treatment arms. The largest reduction in sleep problems was reported within the first 4 weeks of therapy. After treatment discontinuation, sleep quality worsened. Sleep scores demonstrated moderate-to-strong correlation between them, and the change in sleep scores was associated with changes in itch and hives. Improvement in sleep was reported after the first dose of omalizumab. Sleep continued to improve throughout the active treatment period. Patients receiving omalizumab 300 mg achieved greater improvement in sleep than those in other treatment arms. Trial registration ClinicalTrials.gov, NCT01287117 (ASTERIA I), NCT01292473 (ASTERIA II), and NCT01264939 (GLACIAL)
- 1 September 2015
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 106 (7) , 528-532
Manejo diagnóstico y terapéutico de la urticaria crónica por el dermatólogo y papel del servicio de dermatología
- 1 September 2015
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 106 (7) , 528-532
Manejo diagnóstico y terapéutico de la urticaria crónica por el dermatólogo y papel del servicio de dermatología
- 5 April 2015
- Published by Wiley in Contact Dermatitis
- Vol. 72 (6) , 400-402
Is methylisothiazolinone contact allergy a risk factor for polysensitization?
- 5 April 2015
- Published by Wiley in Contact Dermatitis
- Vol. 72 (6) , 400-402
Is methylisothiazolinone contact allergy a risk factor for polysensitization?